



**SENATE AMENDMENT 3,
TO 2003 SENATE RESOLUTION 31**

March 9, 2004 – Offered by Senators ROBSON, MOORE, HANSEN, M. MEYER, ERPENBACH, PLALE, RISSER, DECKER, CHVALA, WIRCH, LASSA, COGGS and CARPENTER.

1 At the locations indicated, amend the resolution as follows:

2 **1.** Page 2, line 13: after that line insert:

3 “Whereas, pharmaceutical companies’ after-tax profits, after expenditures for
4 research and development, averaged 17 percent from 1994 to 1998, compared with
5 5 percent for all other industries; and

6 Whereas, pharmaceutical companies spent \$15.7 billion in 2000 on product
7 promotion despite being protected from competition by current law; and

8 Whereas, pharmaceutical companies from 1993 to 1996 paid an average
9 effective tax rate of 16.2 percent, compared to all other major industries, which paid
10 an average effective tax rate of 27.3 percent; and”.

11 (END)